1 / 10

Uveal Melanoma Market

Uveal melanoma (UM) is a rare malignancy that arises from melanocytes within the uveal tract of the eye.<br>

DelveInsight
Download Presentation

Uveal Melanoma Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Uveal Melanoma - Market Insights, Epidemiology, & Market Forecast 2027 DelveInsight © 2018 | All rights reserved

  2. Introduction Uveal Melanoma : • As the tumor enlarges, it may cause distortion of the pupil (iris melanoma), blurred vision (Ciliary body melanoma), or markedly decreased visual acuity caused by secondary retinal detachment (choroidal melanoma). DelveInsight © 2018 | All rights reserved

  3. Misdiagnoses occur in less than 4% of enucleated eyes at tertiary referral centers. The diagnostic error rate in the Collaborative Ocular Melanoma Study (COMS) was only 0.48%. DIAGNOSIS The diagnostic error rate in the COMS, however, was measured under ideal conditions; all tumors were well visualized and photographed. In real-world situations, the misdiagnosis rate for posterior melanoma may be greater than that reported by the Collaborative Ocular Melanoma Study DelveInsight © 2018 | All rights reserved

  4. Aspects Covered in the Report The report covers the descriptive overview of Uveal Melanoma explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm • The report provides the understanding of the future competition in Uveal Melanoma by reviewing the market drivers and barriers 05 01 04 02 The report also reviews the detailed historical and forecasted Uveal Melanoma market size covering the drug outreach in 7MM The report provides the insight into the epidemiology of the disease and its treatment in the 7 MM 03 The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape DelveInsight © 2018 | All rights reserved

  5. Emerging Drugs And Companies DelveInsight © 2018 | All rights reserved

  6. Market Insight • Despite of Uveal Melanoma’s effective primary therapy, nearly 50% of patients develop metastatic disease. • Several palliative treatments for UM offered in the US and Europe include Liverdirected treatments- Trans arterial Catheter and Immunotherapy, targeted therapy. • As per National Cancer Institute, the mean age-adjusted incidence of Uveal melanoma in the United States is approximately xxx new cases per million people, with no clear variation by latitude • Despite usual success in achieving local control, outcomes for patients with metastatic disease remains impoverished. • h DelveInsight © 2018 | All rights reserved

  7. Complete Information For complete information please click below Or write to us at info@delveinsight.com Click here DelveInsight © 2018 | All rights reserved

  8. About Delveinsight DelveInsight © 2018 | All rights reserved

  9. Services Offered at DelveInsight • Market Size • Market Dynamics • Market Assessment • Trends Analysis • Physicians & Patients Perception • KOLs • Asset Prioritization • Brand Optimization • Portfolio expansion access over 3000+ reports • Therapeutic Assessment • Drug Sales Forecast • Indication Forecast • Clinical Trials Tracking • Competitive landscape • Clinical Trials • Primary Analytics • News-Letters • Conference Tracking • API • Market & Pipeline • Epidemiology • Market Access • Partnership DelveInsight © 2018 | All rights reserved

  10. Contact Us: info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight/ twitter/delveInsight LinkedIn/delveInsight DelveInsight © 2018 | All rights reserved

More Related